EDIT

Editas Medicine Inc

2.62

Oct 02 • 4:00 AM ET +0.10 (3.97%)

Healthcare Biotechnology USA Small NASD

Peers: NTLA CRSP PRME DTIL RGNX ABEO SLN MGTX SLDB VYGR

| Held by: VTI XBI IWM VXF IWO IBB SCHA VTWO VHT IWC

Index	RUT
Market Cap	402.38M
Enterprise Value	261.98M
Income	-73.95M
Sales	47.01M
Book/sh	0.69
Cash/sh	1.38
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	87
IPO	Feb 03, 2016

P/E	-
Forward P/E	-
PEG	-
P/S	8.56
P/B	3.82
P/C	1.90
P/FCF	-
EV/EBITDA	-
EV/Sales	5.57
Quick Ratio	3.19
Current Ratio	3.19
Debt/Eq	0.68
LT Debt/Eq	0.54
Option/Short	Yes / Yes

EPS (ttm)	-0.74
EPS next Y	-0.71
EPS next Q	-0.19
EPS this Y	56.83%
EPS next Y	8.61%
EPS next 5Y	25.35%
EPS past 3/5Y	17.49% 1.84%
Sales past 3/5Y	27.15% -14.89%
EPS Y/Y TTM	73.89%
Sales Y/Y TTM	20.83%
EPS Q/Q	75.77%
Sales Q/Q	232.31%
Earnings	Aug 05 AMC
EPS/Sales Surpr.	44.55% 317.74%

Insider Own	9.80%
Insider Trans	-0.19%
Inst Own	69.35%
Inst Trans	24.23%
ROA	-33.02%
ROE	-118.82%
ROIC	-45.50%
Gross Margin	94.84%
Oper. Margin	-177.56%
Profit Margin	-157.32%
SMA20	-3.78%
SMA50	-7.51%
SMA200	-0.69%
Trades

Shs Outstand	153.53M
Shs Float	138.53M
Short Float	21.63%
Short Ratio	11.97
Short Interest	29.96M
52W High	4.54 -42.26%
52W Low	1.66 57.83%
Volatility	5.71% 6.69%
ATR (14)	0.18
RSI (14)	44.59
Beta	2.10
Rel Volume	0.00
Avg Volume	2.50M
Volume	12

Perf Week	1.55%
Perf Month	-14.94%
Perf Quarter	-28.22%
Perf Half Y	-1.87%
Perf YTD	27.80%
Perf Year	-32.65%
Perf 3Y	-63.31%
Perf 5Y	-93.44%
Perf 10Y	-80.56%
Recom	2.17
Target Price	4.89
Prev Close	2.52
Price	2.62
Change %	3.97%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-23-26	Upgrade	Guggenheim	Neutral → Buy	$5
Aug-18-26	Initiated	Ladenburg Thalmann	Buy	$6
Apr-28-25	Initiated	H.C. Wainwright	Buy	$3
Dec-16-24	Downgrade	JP Morgan	Neutral → Underweight
Dec-13-24	Downgrade	Truist	Buy → Hold
Dec-13-24	Downgrade	Stifel	Buy → Hold	$11 → $3
Dec-13-24	Downgrade	Chardan Capital Markets	Buy → Neutral
Dec-11-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$7 → $4
Nov-25-24	Downgrade	BofA Securities	Buy → Underperform	$13 → $1
Nov-06-24	Upgrade	Evercore ISI	In-line → Outperform
Nov-04-24	Downgrade	Raymond James	Outperform → Mkt Perform
Aug-08-24	Upgrade	BofA Securities	Neutral → Buy	$13 → $15
May-09-24	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$7
Oct-24-23	Upgrade	Citigroup	Neutral → Buy	$11
Oct-18-23	Upgrade	JP Morgan	Underweight → Neutral	$8
Oct-17-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-29-23	Upgrade	Stifel	Hold → Buy	$9 → $17
Jun-12-23	Upgrade	Raymond James	Mkt Perform → Outperform	$17
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight	$15
Dec-13-22	Initiated	Citigroup	Neutral	$11

Show Previous Ratings

Sep-23-26 05:49PM	CRSP, NTLA, BEAM, PRME, EDIT Shares Slip Did Claude Just Spook Gene-Editing Stocks? (Stocktwits) -7.88%
09:49AM	Microsoft upgraded, HubSpot initiated: Wall Street's top analyst calls (The Fly)
Sep-09-26 09:00AM	Editas Medicine Reports Inducement Grants to New Chief Medical Officer (GlobeNewswire) -8.58%
Sep-08-26 07:00AM	Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer (GlobeNewswire) -6.19%
Sep-01-26 09:00AM	Editas Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
05:04PM	Loading…
Aug-05-26 05:04PM	Editas: Q2 Earnings Snapshot (Associated Press) +5.45%
04:01PM	Editas Medicine Announces Second Quarter 2026 Results and Business Updates (GlobeNewswire)
Aug-04-26 04:15PM	Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D. (GlobeNewswire)
May-28-26 04:01PM	Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference (GlobeNewswire)
May-26-26 09:05AM	Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering (GlobeNewswire) +11.59%
06:15AM	Editas Medicine Announces Proposed Public Offering (GlobeNewswire)
06:01AM	Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress (GlobeNewswire)
May-14-26 06:01AM	Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting (GlobeNewswire)
May-05-26 07:16AM	Editas: Q1 Earnings Snapshot (Associated Press)
07:00AM	Editas Medicine Announces First Quarter 2026 Results and Business Updates (GlobeNewswire)
04:31PM	Loading…
Apr-27-26 04:31PM	Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences (GlobeNewswire) +5.88%
Mar-27-26 07:00AM	Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference (GlobeNewswire)
Mar-10-26 11:09AM	EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y (Zacks) +13.79%
Mar-09-26 08:15AM	Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +16.00%
07:11AM	Editas: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates (GlobeNewswire)
Feb-23-26 09:00AM	Editas Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.59%
Dec-10-25 11:30AM	Editas (EDIT) Down 8.3% Since Last Earnings Report: Can It Rebound? (Zacks) +6.56%
Nov-25-25 11:10AM	NVO Stock Down as Rybelsus Misses Goals in 2 Alzheimer's Studies (Zacks)
10:43AM	Biogen Inks Research Deal With Dayra to Boost Immunology Pipeline (Zacks)
Nov-21-25 10:15AM	AZN Wins FDA Nod for Expanded Use of Rare Disease Drug, Koselugo (Zacks)
Nov-20-25 11:38AM	COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know (Zacks)
Nov-18-25 08:48AM	Top 3 Genomics Stocks to Consider for Your Portfolio (Zacks)
Nov-14-25 09:40AM	Is Alto Neuroscience, Inc. (ANRO) Outperforming Other Medical Stocks This Year? (Zacks)
Nov-11-25 10:37AM	Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y (Zacks) +5.56%
08:25AM	Loading…
Nov-10-25 08:25AM	Editas Medicine (EDIT) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
07:24AM	Editas: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Editas Medicine Announces Third Quarter 2025 Results and Business Updates (GlobeNewswire)
Nov-07-25 07:10AM	Gyre Therapeutics, Inc. (GYRE) Q3 Earnings Surpass Estimates (Zacks) -8.18%
Nov-06-25 06:10PM	Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Nov-03-25 09:00AM	Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025 (GlobeNewswire)
Oct-30-25 05:15PM	Gilead Sciences (GILD) Q3 Earnings and Revenues Top Estimates (Zacks)
Oct-09-25 11:01AM	Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress (GlobeNewswire)
Oct-06-25 09:00AM	Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences (GlobeNewswire)
Sep-29-25 12:56AM	Editas Medicine Inc. (EDIT) Confirms EDT-401 as Lead Vivo Program (Insider Monkey) +8.64%
Sep-25-25 09:15AM	Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus (PR Newswire)
Sep-11-25 11:30AM	Why Is Editas (EDIT) Down 16.9% Since Last Earnings Report? (Zacks) +5.86%
Sep-03-25 09:49AM	Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol (Zacks)
Sep-02-25 07:00AM	Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate (GlobeNewswire)
Aug-28-25 04:01PM	Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate (GlobeNewswire)
Aug-27-25 09:00AM	Editas Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-15-25 07:50AM	Why Editas Medicine Stock Was Skyrocketing This Week (Motley Fool)
Aug-13-25 07:30AM	[Latest] Global AI in Synthetic Biology Market Size/Share Worth USD 192.95 Billion by 2034 at a 28.63% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) (GlobeNewswire) +34.50%
Aug-12-25 05:15PM	Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:14PM	Editas: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Editas Medicine Announces Second Quarter 2025 Results and Business Updates (GlobeNewswire)
03:00PM	TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
10:00AM	Can This Beaten-Down Stock Bounce Back? (Motley Fool)
Aug-11-25 08:15AM	Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Jul-31-25 09:40AM	Are Medical Stocks Lagging Editas Medicine (EDIT) This Year? (Zacks)
Jul-30-25 05:40PM	MiMedx (MDXG) Q2 Earnings and Revenues Beat Estimates (Zacks)
09:44AM	3 Genomics Stocks Worth Adding to Your Portfolio in 2025 (Zacks)
Jul-03-25 09:09AM	Editas Surpasses Therapeutic Gene Editing Threshold in New Preclinical Data (Insider Monkey)
Jun-28-25 05:04AM	Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now? (Motley Fool)
Jun-27-25 08:15AM	2 Beaten-Down Stocks to Avoid (Motley Fool) +7.55%
Jun-17-25 10:07AM	Editas Medicine Is Great. Here's Why You Shouldn't Buy It. (Motley Fool)
Jun-12-25 02:01AM	Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June (GlobeNewswire) +7.39%
Jun-11-25 11:30AM	Why Is Editas (EDIT) Up 40% Since Last Earnings Report? (Zacks)
May-25-25 06:00AM	1 Stock Down 97% That Could Double, According to Wall Street (Motley Fool)
May-15-25 07:30PM	Editas Medicine: A Cautionary Tale for Investors (Motley Fool) +8.24%
03:11AM	A new CFO tasked with taking scrappy Editas from last years layoffs into new gene editing territory (Pharma Voice)
May-14-25 09:31AM	Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June (GlobeNewswire) -8.00%
09:00AM	EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top Line (Zacks)
07:01AM	Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire)
May-13-25 09:40AM	Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year? (Zacks)
08:42AM	Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y (Zacks)
07:01AM	Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire)
May-12-25 05:45PM	Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +6.21%
04:48PM	Editas: Q1 Earnings Snapshot (Associated Press Finance)
04:30PM	Editas Medicine Announces First Quarter 2025 Results and Business Updates (GlobeNewswire)
04:01PM	Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board (GlobeNewswire)
12:00PM	Editas (EDIT) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
May-05-25 04:01PM	Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May (GlobeNewswire) -6.10% -13.64%
04:44AM	CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts (Seeking Alpha)
Apr-28-25 04:31PM	Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire)
Apr-04-25 11:30AM	Why Is Editas (EDIT) Down 37.1% Since Last Earnings Report? (Zacks) -8.04%
Apr-03-25 10:48AM	Editas Medicine: Do The Risks Outweigh The Rewards? (Seeking Alpha) -5.08%
Mar-21-25 08:15AM	AstraZeneca deepens China investment; Editas loses CFO to Dyne (BioPharma Dive)
Mar-20-25 04:12PM	Editas Medicine promotes Amy Parison as CFO (SeekingAlpha)
04:01PM	Editas Medicine Announces Chief Financial Officer Transition (GlobeNewswire)
Mar-05-25 05:25PM	Editas Medicine (EDIT) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +16.48% -13.17%
04:19PM	Editas: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates (GlobeNewswire)
Feb-24-25 09:00AM	Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March (GlobeNewswire)
Jan-14-25 09:30AM	Editas Medicine Outlines 2025 Strategic Priorities and Milestones (TipRanks)
Jan-13-25 09:00AM	Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities (GlobeNewswire) -7.94%
Jan-06-25 09:00AM	Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +6.72%
Dec-30-24 03:11PM	Why Is Editas Medicine, Inc. (EDIT) Among the Top CRISPR Stocks to Invest In? (Insider Monkey)
Dec-14-24 07:01AM	Editas Medicine price target lowered to $8 from $10 at Baird (TipRanks)
Dec-13-24 02:15PM	Brokerages downgrade gene editing company Editas to 'hold', shares slump 23% (Investing.com) -23.81%
01:26PM	Editas Medicine Reshapes Future with In Vivo Focus Amid Major Workforce Cuts (GuruFocus.com)
06:44AM	Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026 (Benzinga)
Dec-12-24 04:00PM	Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years (GlobeNewswire) -5.03%
12:37PM	Editas to lay off staff after search for sickle cell partner comes up empty (BioPharma Dive)
Dec-09-24 12:00PM	Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu on September 3, 2013 and is headquartered in Cambridge, MA.

PresidentDr. Gilmore O'Neill M.D.

Senior VP & CFOMs. Amy Parison

Executive VP & Chief Scientific OfficerDr. Linda C. Burkly Ph.D.

Co-Founder & Scientific Advisory Board MemberDr. Feng Zhang Ph.D.

Co-Founder & Scientific Advisory Board MemberDr. George McDonald Church Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Burkly Linda	EVP, CHIEF SCIENTIFIC OFFICER	Sep 03 '26	Sale	3.04	709	2,153	61,660	Sep 04 04:27 PM
Parison Amy	SVP, Chief Financial Officer	Sep 03 '26	Sale	3.04	453	1,376	13,839	Sep 04 04:25 PM
O'Neill Gilmore Neil	CEO	Sep 03 '26	Sale	3.04	5,124	15,563	243,189	Sep 04 04:22 PM
O'Neill Gilmore Neil	Officer	Sep 03 '26	Proposed Sale	3.28	5,100	16,728		Aug 31 04:11 PM
Burkly Linda	Officer	Sep 03 '26	Proposed Sale	3.28	700	2,296		Aug 31 04:09 PM
Parison Amy	SVP, Chief Financial Officer	Aug 03 '26	Sale	2.58	678	1,749	14,292	Aug 05 04:07 PM
Burkly Linda	EVP, CHIEF SCIENTIFIC OFFICER	Jul 28 '26	Sale	2.67	4,928	13,158	62,369	Jul 29 04:51 PM
Burkly Linda	Officer	Jul 27 '26	Proposed Sale	2.88	5,500	15,840		Jul 21 04:37 PM
Parison Amy	SVP, Chief Financial Officer	Jun 03 '26	Sale	2.70	464	1,253	14,970	Jun 05 04:33 PM
O'Neill Gilmore Neil	CEO	Jun 03 '26	Sale	2.70	15,380	41,543	248,313	Jun 05 04:33 PM
Burkly Linda	EVP, CHIEF SCIENTIFIC OFFICER	Jun 03 '26	Sale	2.70	731	1,975	67,297	Jun 05 04:32 PM
O'Neill Gilmore Neil	Officer	Jun 03 '26	Proposed Sale	3.08	15,000	46,200		May 29 04:40 PM
O'Neill Gilmore Neil	CEO	Mar 03 '26	Sale	2.02	5,394	10,894	263,693	Mar 04 04:56 PM
Parison Amy	SVP, Chief Financial Officer	Mar 03 '26	Sale	2.02	474	957	15,434	Mar 04 04:49 PM
Burkly Linda	EVP, CHIEF SCIENTIFIC OFFICER	Mar 03 '26	Sale	2.02	749	1,513	68,028	Mar 04 04:48 PM
O'Neill Gilmore Neil	Officer	Mar 03 '26	Proposed Sale	1.89	6,000	11,340		Feb 27 04:35 PM
Burkly Linda	EVP, CHIEF SCIENTIFIC OFFICER	Dec 03 '25	Sale	2.15	713	1,535	68,777	Dec 04 04:39 PM
O'Neill Gilmore Neil	CEO	Dec 03 '25	Sale	2.15	5,603	12,064	269,087	Dec 04 04:38 PM
Parison Amy	SVP, Chief Financial Officer	Dec 03 '25	Sale	2.15	461	993	15,908	Dec 04 04:38 PM
O'Neill Gilmore Neil	Officer	Dec 03 '25	Proposed Sale	2.50	7,000	17,500		Dec 01 05:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EDIT

Editas Medicine Inc

Upgrade your Finviz experience